Prisms to Shift Pain Away: Pathophysiological and Therapeutic Exploration of CRPS with Prism Adaptation

Table 1

Patients’ description.

Patient	Gender	Age	Dominant hand	Type	Affected side	Disease duration (months)	Mean pain intensity (VAS 0–100) over the last week	Treatment	Previous care
Ms. H.	F	50	R	1	L	36 M	50	(i) Paracetamol; (ii) Amitriptyline; (iii) Paroxetine; (iv) Alprazolam	(i) Physiotherapy + occupational therapy; (ii) Analgesics, levels 1, 2, and 3; (iii) TENS
Ms. F.	F	51	R	1	L	4 M	75	(i) Lidocaine patch; (ii) Flavonoid fraction; (iii) Amitriptyline	Analgesic only
Mr. D.	M	30	R	2	R	6 M	70	(i) Morphine sulfate; (ii) Nefopam; (iii) Paracetamol; (iv) Clobazam; (v) Gabapentin	(i) Mirror therapy; (ii) Physiotherapy + occupational therapy
Ms. A.	F	55	R	1	R	17 M	38.5	(i) Duloxetine; (ii) Paracetamol; (iii) Zopiclone	(i) Physiotherapy + occupational therapy; (ii) Mirror therapy; (iii) Sympathetic blockades × 6
Ms. dCS.	F	24	R	1	R	4 M	55	(i) Amitriptyline; (ii) Paracetamol; (iii) Lidocaine patch; (iv) Phytotherapy	(i) Physiotherapy; (ii) TENS
Ms. O.	F	43	R	1	R	20 M	65	(i) Paracetamol; (ii) Codeine	(i) Physiotherapy; (ii) TENS; (iii) Specialized follow-up
Ms. C.	F	58	R	1	R	6 M	55	(i) Paracetamol; (ii) Tramadol; (iii) Amitriptyline	(i) Physiotherapy

There were 6 women and one man, aged from 24 to 58. Five patients presented CRPS type 1 and two patients presented CRPS type 2. They all underwent various care before inclusion.